Atavistik Bio has initiated a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ATV-1601, an investigational selective AKT1 allosteric inhibitor, in patients with Hereditary Hemorrhagic Telangiectasia (HHT). We understand that some patients may wish to access this investigational drug that has not yet been approved. At this early stage of drug development, ATV-1601 is being used exclusively in clinical research trials evaluating its safety and efficacy. Therefore, Atavistik Bio does not currently offer an expanded access (compassionate use) program. We believe the most appropriate way for patients to access ATV-1601 is by participating in our clinical trial, and we encourage patients to speak with their doctors about whether they may qualify. Information regarding our ongoing clinical trials, including any open and enrolling sites, can be accessed at www.clinicaltrials.gov.

If you are a patient and have additional questions about Atavistik Bio’s expanded access policy or access to ATV-1601, please talk to your doctor. If you are a healthcare provider who is interested in learning more about ATV-1601 or participation in one of our trials, please submit a request to Studydirector@atavistikbio.com, and we will endeavor to respond within 5 business days.

Atavistik Bio reserves the right to update this expanded access policy at any time.